Educational research & price index · Independent Janoshik & MZ Biolabs COA verification

← Verified COAs & $/mg for this compound

Guide|20 CitationsHormonal & GHFemale-friendly

Ipamorelin Research Dosing Reference

Also known as: NNC 26-0161, Selective Ghrelin Mimetic (GHRP)

Dose Range
100–300 mcgResearch range
0Typical research window: 100–300 mcg400 mcg

Studied in human pharmacokinetic & GI motility trials. Commonly researched at 100–300 mcg SubQ before sleep.

Protocol at a Glance
How Often
1–2× daily

Once nightly before bed (or AM fasted + PM pre-bed, 5 days on / 2 off)

A Typical Run
8–12 weeks

8–12 weeks on cycle followed by a 4-week pituitary washout.

How It's Taken
Vial

SubQ injection (fasted)

Evidence
Clinical Trials

Human Phase 2 clinical trials & endocrine selectivity studies

Half-Life & 72-Hour Clearance Shape
~2 hours

~2 hours terminal half-life; selective ghrelin mimetic without ACTH/cortisol/prolactin spike

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 100 mcg4 units
High end: 300 mcg12 units

All U-100: 100 units = 1 mL. 50 doses in the vial at the low end (16 doses at the high end).

Track the doses you run

Save Ipamorelin to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

Ipamorelin supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$25.00 net$50.00
5mg Lyophilized Vial
$5.00/mg$10.00/mg retail
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$50.00
10mg vial
$5.00/mg
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$55.00
10mg vial
$5.50/mg
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$57.00
10mg vial
$5.70/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$79.00
10mg vial
$7.90/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$80.00
10mg vial
$8.00/mg
BioLongevity Labs
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$79.97
10mg vial
$8.00/mg
Core Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$43.00
5mg vial
$8.60/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$43.99
5mg vial
$8.80/mg
Biotech Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$46.00
5mg vial
$9.20/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

2026 FDA 503A Cat-2 UpdateTier 2 — Human Phase 1/2 Clinical Data
Pharmacological Class
Pituitary Growth Hormone Secretagogue (GHRH Analog / Ghrelin Receptor Agonist)
Administration Route
Under-the-skin injection (Subcutaneous)
2026 FDA & 503A Status
Not FDA-approved. In April 2026, the FDA removed 14 peptides (including BPC-157, Thymosin Beta-4/TB-500, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, and DSIP) from the Category 2 503A Interim Bulks List pending formal July 2026 PCAC rulemaking. Available as COA-verified research reference standards or via specialized physician telehealth guidance.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S2.2 (Peptide Hormones, Growth Factors, GH Fragments, BPC-157 & Thymosin-β4)
Evidence Tier
Tier 2 — Human Phase 1/2 Clinical Data: Published human Phase 1/2 clinical studies, regional regulatory approval, or controlled human biomarker trials
What is a Growth Hormone Secretagogue?

A compound that stimulates your pituitary gland to release more of its own growth hormone (GH). Unlike synthetic GH injection, secretagogues trigger natural pulsatile GH release. Examples: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin. MK-677 (Ibutamoren) is technically not a peptide but acts as an oral GH secretagogue.

Bottom Line Up Front

Ipamorelin is a selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the "cleaner" GHRPs with fewer side effects than GHRP-6 or GHRP-2.

Best evidence for

Growth hormone stimulation, recovery

Weakest evidence for

Significant muscle growth in healthy adults

Pharma equivalent

None

Studies on file

20 (7 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Ipamorelin is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Ipamorelin is a growth hormone secretagogue that selectively stimulates the pituitary gland to release growth hormone. It is one of the most selective GHRPs studied.

Mechanisms of Action

  • Selective GH release
  • Minimal cortisol/prolactin increase
  • Ghrelin receptor agonist
  • Preserves natural GH pulsatility

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
GH Release Study
reported protocol
100 μg3x daily4 weeksSubcutaneoushuman
Baseline & Mid-Cycle Biomarker Bloodwork Panel

GH / IGF-1 & Glycemic Sensitivity Biomarker Panel (Ipamorelin)

Growth hormone secretagogues and somatomedin analogs directly elevate hepatic IGF-1 and can shift fasting insulin sensitivity via GH counter-regulatory signaling.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

Serum IGF-1 (LC/MS) + Z-Score

Day 0 + Wk 6–8

Why track at baseline: Establishes baseline somatotropic output before pituitary or local IGF-1R stimulation.

Week 6–8 check: Confirm physiological upper-quartile elevation (typically +30% to +80% above baseline) without supraphysiological overshoot (>300 ng/mL).

Fasting Insulin & HOMA-IR

Day 0 + Wk 6–8

Why track at baseline: Pituitary GH pulses promote free fatty acid mobilization, which can transiently reduce peripheral insulin sensitivity.

Week 6–8 check: Keep Fasting Insulin <6–8 uIU/mL; if elevated, enforce strict 2–3 hr pre-bed fasting before GH secretagogue administration.

HbA1c & Fasting Plasma Glucose

Day 0 + Wk 6–8

Why track at baseline: Screens for subclinical prediabetes prior to growth-factor or secretagogue exposure.

Week 6–8 check: Verify stable 90-day glycemic control (HbA1c <5.4% optimal) at Week 6–8.

hs-CRP, Prolactin & CMP

Day 0 + Wk 6–8

Why track at baseline: Checks systemic inflammation, pituitary selectivity (no off-target prolactin/cortisol rise), and hepatic/renal clearance.

Week 6–8 check: Confirm Ipamorelin/CJC/Tesamorelin selectivity with unchanged Prolactin and normal liver transaminases.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

7 Human13 Animal

Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.

Limitations: No placebo control reported. Review article — no new primary data.

2026|Journal of the American Academy of Orthopaedic Surgeons. Global research &amp; reviews
PubMed

BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability.

Limitations: No placebo control reported. Review article — no new primary data.

2026|The American journal of sports medicine
PubMed

Furthermore, the concentrations of luteinizing hormone (LH) and 11-ketotestosterone (11-KT) in the serum of fish treated with either 5 or 30&#x202f;&#xb5;g of IPA were significantly elevated in comparison to the control group. Collectively, these findings suggest that the administration of ghrelin enhances the development of germ cells during the meiosis-I phase and that this effect might be mediated via the stimulation of 11-KT and androgen receptors at the testicular level and LH at the pituitary level in the tilapia.

Limitations: Animal study only — human translation uncertain.

2024|Animal reproduction science
PubMed

had beneficial effects in alleviating cisplatin-induced weight loss during delayed phase, and these effects were seen when centrally administered anamorelin. Anamorelin inhibited cisplatin-induced acute emesis following intracerebroventricular but not intraperitoneal administration, suggesting that brain penetration is important for its anti-emetic mechanism of action.

Limitations: Animal study only — human translation uncertain.

2024|Physiology &amp; behavior
PubMed

All are potent GH and IGF-1 stimulators that can significantly improve body composition while ameliorating specific hypogonadal symptoms including fat gain and muscular atrophy. However, a paucity of data examining the clinical effects of these compounds currently limits our understanding of GHS' role in the treatment of men with hypogonadism, but does open opportunities for future investigation.

Limitations: No placebo control reported. Review article — no new primary data.

2020|Translational andrology and urology
PubMed

The structure of these peptides was characterised by means of high resolution (tandem) mass spectrometry, and for Gly-Ipamorelin and Gly-GHRP-2 their identity was additionally confirmed by custom synthesis. Further, established in-vitro experiments provided preliminary information considering the potential metabolism after administration.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported.

2018|Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
PubMed

Abdominal surgery caused a delay in gastric emptying with 78% &#xb1; 5% of the meal remaining in the stomach in vehicle controls. Ipamorelin (0.014 &#xb5;mol/kg intravenous) resulted in a significant acceleration (P < 0.05 vs vehicle-treated rat) of gastric emptying with 52% &#xb1; 11% of the meal remaining in the stomach compared to nonsurgical control animals with 44% &#xb1; 6%.

Limitations: Animal study only — human translation uncertain.

2016|Journal of experimental pharmacology
PubMed

The method was fully validated, calibration curves of targeted analytes were obtained and excretion curves of GHRPs and their metabolites were plotted. Our results confirm that the detection window after GHRPs administration depends on individual metabolism, drug preparation form and the way of administration.

Limitations: No placebo control reported.

2016|Drug testing and analysis
PubMed

One hundred seventeen patients were enrolled, of whom 114 patients composed the safety and modified intent-to-treat populations. Demographic and disease characteristics were balanced between groups.

Limitations: Standard limitations apply. Check original paper for full discussion.

2015|International journal of colorectal disease
PubMed

In contrast, repetitive dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased the cumulative fecal pellet output, food intake, and body weight gain. The results suggest that postsurgical intravenous infusions of ipamorelin may ameliorate the symptoms in patients with POI.

Limitations: Animal study only — human translation uncertain.

2009|The Journal of pharmacology and experimental therapeutics
PubMed

Ipamorelin evoked significant (p<0.04) increases in insulin secretion from the pancreas of normal and diabetic rats. Either diltiazem or yohimbine or propranolol or a combination of atropine, propranolol and yohimbine inhibited IPA-evoked insulin secretion significantly (p<0.03) from the pancreas of normal and diabetic rats.

Limitations: Animal study only — human translation uncertain.

2005|Neuro endocrinology letters
PubMed

Only in the Ipamorelin group did Ipamorelin (10(-8) M), GHRP 6 (10(-8) M) and GHRH (10(-8) M) prompt increased intracellular GH content. These data suggest that, at least in the young female rat, the GHS Ipamorelin is able to exert a dynamic control effect on the somatotroph population and on GH hormone content.

Limitations: Animal study only — human translation uncertain.

2003|Histology and histopathology
PubMed

The maximum tetanic tension was increased significantly, and the periosteal bone formation rate increased four-fold in animals injected with GC and GHS in combination, compared with the group injected with GC alone. In conclusion, the decrease in muscle strength and bone formation found in GC-injected rats was counteracted by simultaneous administration of the growth hormone secretagogue.

Limitations: Animal study only — human translation uncertain.

2002|Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
PubMed

A series of NN703 analogues with lysine mimetics combined with naphthyl- or biphenylalanine in the core has been prepared and tested in vitro in a rat pituitary cell based assay and subsequently in vivo in pigs in a single dose at 50 nmol/kg. Re-introduction of certain pharmacophores in the C-terminal of NN703, which were originally removed during optimisation for oral bioavailability, led to unexpectedly potent compounds in vitro as well as in vivo.

Limitations: Animal study only — human translation uncertain.

2001|Bioorganic &amp; medicinal chemistry letters
PubMed

We conclude that treatment of adult female rats with the GHSs ipamorelin and GHRP-6 increases BMC as measured by DXA in vivo. The results of in vitro measurements using pQCT and Archimedes' principle, in addition to ash weight determinations, show that the increases in cortical and total BMC were due to an increased growth of the bones with increased bone dimensions, whereas the volumetric BMD was unchanged.

Limitations: Animal study only — human translation uncertain.

2000|The Journal of endocrinology
PubMed

The pituitary GH content was unchanged by ipamorelin treatment. Whether ipamorelin or other GH secretagogues may have a place in the treatment of children with growth retardation requires demonstration in future clinical studies.

Limitations: Animal study only — human translation uncertain.

1999|Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
PubMed

The PK parameters showed dose-proportionality, with a short terminal half-life of 2 hours, a clearance of 0.078 L/h/kg and a volume of distribution at steady-state of 0.22 L/kg. The time course of GH stimulation by ipamorelin showed a single episode of GH release with a peak at 0.67 hours and an exponential decline to negligible GH concentration at all doses.

Limitations: No placebo control reported.

1999|Pharmaceutical research
PubMed

Higher bioavailabilities of approximately 50% were determined for NNC 26-0235, NNC 26-0194 and GHRP-2, whereas the nasal absorption of GHRP-6 was somewhat lower. Thus, the peptides could be easily transported across the nasal epithelium suggesting that the nasal route seems promising for systemic delivery of this family of peptidyl growth hormone secretagogues.

Limitations: Animal study only — human translation uncertain.

1999|Xenobiotica; the fate of foreign compounds in biological systems
PubMed

In conclusion, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development.

Limitations: Animal study only — human translation uncertain.

1998|European journal of endocrinology
PubMed

NNC 26-0235 demonstrated a 10% oral bioavailability in dogs, and NNC 26-0235 and ipamorelin were able to increase basal GH level by more than 10-fold after oral administration of a dose of 1.8 and 2.7 mg/kg, respectively. The tripeptide NNC 26-0323 (3-(aminomethyl)benzoic acid-N-Me-D-2Nal-N-Me-D-Phe-ol) which showed moderate in vitro potency but lacked in vivo potency demonstrated a 20% oral bioavailability in rats.

Limitations: Animal study only — human translation uncertain.

1998|Journal of medicinal chemistry
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Hormone modulation requires monitoring
  • •Not for unsupervised use
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Ipamorelin, baseline labs & clinician oversight.

Full Ipamorelin $/mg comparison →
50% OFF AUTO-APPLIED$5.00/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy Ipamorelin: best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Ascension Peptides — $5.00/mg (5mg Lyophilized Vial, $25.00)
  2. 2. Polaris Peptides — $5.00/mg (10mg vial, $50.00)
  3. 3. Elite Research USA — $5.50/mg (10mg vial, $55.00)

Where is the cheapest place to buy Ipamorelin?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $5.00/mg (5mg Lyophilized Vial, $25.00 after the 50% new-customer partner-link discount). We compared 10 US suppliers with live, checked prices.

How much does Ipamorelin cost per mg?

Verified US domestic prices currently range from $5.00/mg to $9.20/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is Ipamorelin approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Popular Stacks

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.